Lorcaserin in obesity: minimal benefits and ill-defined harms
- PMID: 30700436
- DOI: 10.1136/bmjebm-2018-111128
Lorcaserin in obesity: minimal benefits and ill-defined harms
Keywords: clinical trials.
Conflict of interest statement
Competing interests: IJO and JKA are coauthors of a previously published systematic review and meta-analysis that assessed the benefits and harms of centrally acting antiobesity medicines. IJO holds grant funding from the NIHR School of Primary Care Research (NIHR Evidence Synthesis working group Project No 390).
Comment on
-
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.N Engl J Med. 2018 Sep 20;379(12):1107-1117. doi: 10.1056/NEJMoa1808721. Epub 2018 Aug 26. N Engl J Med. 2018. PMID: 30145941 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical